2-(Morpholin-4-yl)isonicotinic acid → N-[1-(4-Chloro-3-ethoxy-benzyl)piperidin-4-yl]-2-morpholin-4-yl-isonicotinamide

HRID 502332

반응식

HRID 502332 반응식
[Cl:1][C:2]1[CH:15]=[CH:14][C:5]([CH2:6][N:7]2[CH2:12][CH2:11][CH:10]([NH2:13])[CH2:9][CH2:8]2)=[CH:4][C:3]=1[O:16][CH2:17][CH3:18].[N:19]1([C:25]2[CH:30]=[C:29]([C:31](O)=[O:32])[CH:28]=[CH:27][N:26]=2)[CH2:24][CH2:23][O:22][CH2:21][CH2:20]1>>[Cl:1][C:2]1[CH:15]=[CH:14][C:5]([CH2:6][N:7]2[CH2:12][CH2:11][CH:10]([NH:13][C:31](=[O:32])[C:29]3[CH:28]=[CH:27][N:26]=[C:25]([N:19]4[CH2:20][CH2:21][O:22][CH2:23][CH2:24]4)[CH:30]=3)[CH2:9][CH2:8]2)=[CH:4][C:3]=1[O:16][CH2:17][CH3:18]

참가 물질

3

실험 절차

The title compound (16 mg, 34%) was prepared analogously to example 1 by coupling of 1-(4-chloro-3-ethoxy-benzyl)piperidin-4-ylamine with 2-(4-morpholinyl)-4-pyridinecarboxylic acid. MS: 459.4 (MH+)

출처 및 근거

ORD 기록
ord-395af3589c2942598d92f9ca82a6735c
출처 데이터셋
uspto-grants-2010_08
특허 번호
US07772253B2

연결된 노트

불러오는 중…